Mirum Pharmaceuticals, Inc. - common stock (MIRM) News
Filter MIRM News Items
MIRM News Results
|Loading, please wait...|
MIRM News Highlights
- For MIRM, its 30 day story count is now at 7.
- Over the past 22 days, the trend for MIRM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- PEAK are the most mentioned tickers in articles about MIRM.
Latest MIRM News From Around the Web
Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.
Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) Stock Jumped 29.45% Over A Month Are There Any Chances Of Growth?
During the last session, Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)s traded shares were 0.35 million. At the end of the trading day, the stocks price was $23.12, reflecting an intraday gain of 1.67% or $0.38. The 52-week high for the MIRM share is $23.35, that puts it down -0.99 from that peak though still a striking 44.55% Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) Stock Jumped 29.45% Over A Month Are There Any Chances Of Growth? Read More »
Mirum Pharmaceuticals' (NASDAQ:MIRM) investors will be pleased with their 14% return over the last year
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...
Mirum Pharmaceuticals (MIRM) granted two new employees non-qualified stock options to buy 14.2K common shares and 7.1K restricted stock units under the company''s 2020 Inducement…
FOSTER CITY, Calif., February 11, 2022--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
In a report released today, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report), with a price target of $46.00. The company's shares closed last Thursday at $17.10. According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -22.3% and a 33.6% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $56.20 average price target.
There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Mirum Pharmaceuticals (MIRM – Research Report) with bullish sentiments. Mirum Pharmaceuticals (MIRM) In a report issued on January 11, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals. The company's shares closed last Friday at $18.74. According to TipRanks.
Investment company Mesirow Financial Investment Management, Inc. (Current Portfolio) buys Green Brick Partners Inc, Cadre Holdings Inc, Identiv Inc, Atlanticus Holdings Corp, Andersons Inc, sells TriState Capital Holdings Inc, The Joint Corp, Mirum Pharmaceuticals Inc, Genasys Inc, CareDx Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mesirow Financial Investment Management, Inc..
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report), with a price target of $64.00. The company's shares closed last Tuesday at $15.92. According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.4% and a 38.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals. Mirum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $57.67.
FOSTER CITY, Calif., January 11, 2022--Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones